CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

307 papers

Showing 37-48 of total 307 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.

Ismail M; Al-Gizey N; Alabed Z; Mustafa N; Al-Najjar E; Hamdaneh Y; Eid N; Esmail A

2026PubMedDirectly related

AI-powered biotherapies: Artificial intelligence and informatics at the intersection of transfusion medicine and biotherapies.

Goel R; Land K; Schoen B; Vassallo R; Cap B

Jan 1, 2026Transfusion

2026PubMedDirectly related

The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model.

Schneider MMK; Müller G; Herbst S; Slesaczeck J; Schmädig R; Schmidt F; Illmer T; Leppla L; Valenta S; De Geest S; Teynor A; Wolfien M; Ernst A; Bischof L; Schmitt J; Hänel M; Metzeler KH; Platzbecker U; Vučinić V; Schetelig J; Bornhäuser M; Middeke JM; Egger-Heidrich K

Jan 1, 2026Annals of hematology

2026PubMedSupporting evidence

From blood to biotherapies: A brief historical perspective.

Cancelas JA; Delaney M; Schäfer R

Jan 1, 2026Transfusion

2026PubMedDirectly related

Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).

Li Z; Xiao Z

Jan 1, 2026Oncology letters

2026PubMedDirectly related

Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation.

Zuber M; Tan CJ; Caballero J; Somanath PR; Godara A; Elshafie S; Zapata LV

Jan 1, 2026Transplantation and cellular therapy

2026PubMedSupporting evidence

B-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies.

Salomova N; Khachatryan LG; Amonov A; Normatov M; Khalmatova N; Rashidov A; Babamuratov B

Jan 1, 2026Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

2026PubMedSupporting evidence

Transduction efficiency in clinical CAR T cell products: A retrospective study at a single center.

Shao L; Prochazkova M; Cai Y; Lee Han K; Martin K; Shi R; Yang R; Ma J; Zheng Y; Garces P; Frodigh SE; Pham V; Zhang N; Somerville RP; Stroncek DF; Jin P

Jan 1, 2026Molecular therapy. Advances

2026PubMedDirectly related

In vivo CAR T-cell therapy: determinants of response and durability.

Abou-El-Enein M

Jan 1, 2026Blood cancer discovery

2026PubMedDirectly related

Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies.

Guidetti A; Dogliotti I; Chiappella A; Iannitto E; Evangelista A; Dodero A; Di Rocco A; Balzarotti M; Casadei B; Cavallo F; Re A; Farina M; Bramanti S; Chiusolo P; Martino M; Musso M; Zanni M; Grillo G; Ravano E; Krampera M; Hohaus S; Martelli M; Zacchi G; Visco C; Zinzani PL; Consoli U; Corradini P

Jan 1, 2026Haematologica

2026PubMedDirectly related

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy.

Zhang X; Xia F; Qi K; Xia J; Zhou D; Sun Q; Zhang H; Wang X; Sang W; Li D; Yan Z; Chang AH; Cao J; Pan B

Jan 1, 2026Haematologica

2026PubMedDirectly related

A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy.

Jordana-Urriza L; Muraro MG; Du M; Lambrecht V; Rodriguez-Madoz JR; Martin I; García-García A

Jan 1, 2026Frontiers in bioengineering and biotechnology